Context: Critical illness induces swelling, enlargement, and dysfunction of mitochondria, which in liver, but not in muscle, is aggravated by excessive hyperglycemia. We previously demonstrated impaired autophagic clearance of damaged mitochondria in fed prolonged critically ill patients. Impaired fusion/fission-mediated repair and/or renewal through biogenesis may further accentuate mitochondrial abnormalities.
C
ritically ill patients face a high risk of death, which is usually the consequence of nonresolving multiple organ failure, irrespective of intensive care unit (ICU) admission diagnosis. Patient and animal studies found an association of mitochondrial dysfunction with severity of organ dysfunction and risk of adverse outcome of critical illness (1, 2) . Pronounced hyperglycemia, which develops in response to illness or trauma and is worsened by artificial (parenteral) nutrition, aggravates such mitochondrial damage. This is supported by the observation that insulin-titrated normoglycemia protects mitochondrial morphology and function (3), which appears explained by avoidance of damage by cellular glucose overload rather than direct protection by insulin (4, 5) .
We recently demonstrated that activation of autophagy, the pathway responsible for clearance of damaged organelles and potentially toxic protein aggregates, is impaired in liver and muscle of fed prolonged critically ill patients (6) . This may have contributed to the persistent mitochondrial structural damage and dysfunction. However, disturbances in two other major mechanisms that repair or compensate for mitochondrial damage may have played a role as well. In this regard, mitochondrial fusion and fission allow exchange of damaged components leading to dilution of molecular damage or bundling of dysfunctional structures in a single, irreversibly damaged organelle that is subsequently targeted for removal by autophagy (7, 8) . Mitochondrial biogenesis generates new mitochondria when needed, such as in response to mitochondrial damage and increased energy demand (9) . Figure 1 shows a simplified schematic overview of the mitochondrial repair mechanisms.
We hypothesized that impaired mitochondrial fusion or fission and/or compromised activation of mitochondrial biogenesis could contribute to mitochondrial dysfunction in critical illness. We also investigated whether the partial alleviation of such damage by preventing hyperglycemia could in part be mediated via these pathways. We therefore studied several key readouts of mitochondrial dynamics in liver and skeletal muscle biopsies obtained from critically ill patients.
Patients and Methods

Patients
We studied liver and rectus abdominis biopsies taken within 30 Ϯ 20 min after death from 36 randomly selected surgical ICU
FIG. 1.
Simplified scheme of the mitochondrial repair mechanisms and their interaction. Mitochondria are subjected to frequent cycles of fusion and fission. Mitochondrial fusion requires participation of the mitofusins on the outer mitochondrial membrane and OPA1 in the intermembrane space, whereas recruitment of Drp1 from the cytosol to the mitochondria by the outer membrane protein Fis1 is necessary for mitochondrial fission. Fusion and fission events are important in determining the overall shape of the mitochondria and potentiate dilution of damage over different organelles. They are also involved in mitochondrial biogenesis as well as autophagy of these organelles (mitophagy), which normally balances biogenesis. Generation of uneven daughter organelles by asymmetric fission segregates the daughter unit that contains most of the defects, has an impaired fusion capacity (due to low membrane potential ⌬ m and OPA1 content), and is predisposed to removal by autophagy. Autophagy is an inducible, complex process that starts with the formation of a phagophore or isolation membrane, which is elongated to surround portions of cytoplasm and/or organelles with the formation of an autophagosome. The mature autophagosome fuses with a lysosome to form an autolysosome, containing all enzymes for degradation of the invaginated content. Multiple transcriptional pathways operate in the control of both nuclear and mitochondrial gene expression to regulate mitochondrial biogenesis. RIP-140 inhibits mitochondrial biogenesis. Peroxisome proliferator-activated receptor-␥ coactivator-1␣ (PGC-1␣) promotes mitochondrial biogenesis through regulation of nuclear respiratory factor-1 (NRF-1) and NRF-2. Nuclear respiratory factors regulate TFAM, Pol-␥ and single-strand binding protein (SSB), which in turn direct mtDNA replication and transcription of several mtDNA-encoded respiratory chain complex subunits. NRF-1 and NRF-2 also directly regulate other proteins with the corresponding response elements in their promoter, including nDNA-encoded respiratory chain complex subunits.
patients and vastus lateralis biopsies taken in vivo from 24 randomly selected medical ICU patients included in two randomized, controlled clinical studies on intensive insulin therapy (10, 11) . Postmortem vastus lateralis biopsies were available from a subgroup of the surgical ICU patients (n ϭ 14). Patients were optimally matched for baseline characteristics and compared with gender-, age-, and body mass index-matched controls as previously described (6) . In each group of critically ill patients, 50% had been assigned to intensive insulin therapy to maintain blood glucose levels between 80 -110 mg/dl (4.4 -6.1 mmol/liter, normoglycemia), whereas the other 50% received conventional insulin therapy, during which insulin was administered only if glucose levels exceeded 215 mg/dl and stopped when glucose levels fell below 180 mg/dl. As controls, we analyzed liver and rectus abdominis biopsies harvested intraoperatively from 18 patients not suffering from generalized disease and undergoing uncomplicated elective abdominal surgery for restorative rectal resection and vastus lateralis biopsies from five healthy volunteers.
Written informed consent was obtained from volunteers, patients, or closest family member. The Katholieke Universiteit Leuven Institutional Review Board approved study protocols and consent forms (ML1094, ML1820, ML2707).
Tissue analyses
Antibodies for Western blot were purchased from Abcam (Cambridge, UK) [mitofusin-2, optic atrophy-1 (OPA1), dynamin-related protein-1 (Drp1), fission-1 (Fis1), receptor-inhibitory protein-140 (RIP-140), mitochondrial DNA (mtDNA) polymerase-␥ (Pol-␥), mitochondrial transcription factor-A (TFAM), and cytokeratin-18], Molecular Probes (Eugene, OR) (ND6 and NDUFA9), or DakoCytomation (Glostrup, Denmark) (horseradish peroxidase-conjugated goat antirabbit or rabbit antimouse antibodies). Cytokeratin-18 (liver) and actin levels (muscle) were measured to control for equal loading. Protein levels were normalized to median control levels. After DNA extraction and ribonuclease treatment (GenElute Mammalian Genomic DNA Miniprep kit; Sigma-Aldrich, Bornem, Belgium), mtDNA content was determined (12) by amplification of a mtDNA-encoded ND5 fragment (Hs02596878_g1; Applied Biosystems, Foster City, CA) and a nuclear DNA (nDNA)-encoded cystic fibrosis transmembrane conductance-regulator fragment (5Ј-TGGCACCATTAAAGAAAATATCATCT-3Ј forward primer, 5Ј-GAAGGGTTCATATGCATAATCAAAAA-3Ј reverse primer,and5Ј-TAGATACAGAAGCGTCATCAAAGCATGCCA-3Ј probe;Eurogentec, Seraing, Belgium). All analyses were performed blinded for group allocation.
Statistical analyses
Differences analyzed by Kruskal-Wallis and Mann-Whitney U test were considered statistically significant when two-sided P values were Ͻ0.05 (StatView version 5.0.1; SAS Institute, Cary, NC).
Results
Blood glucose and insulin infusion
Mean morning blood glucose levels during the ICU stay of surgical critically ill patients were 178 Ϯ 16 mg/dl (mean Ϯ SD) in the conventional and 101 Ϯ 7 mg/dl in the intensive insulin therapy group (P Ͻ 0.0001). Patients received a median (interquartile range) insulin dose of 14 (2-34) and 44 (23-87) IU/d, respectively (P ϭ 0.005). The mean morning blood glucose levels of medical critically ill patients were 156 Ϯ 26 mg/dl in the conventional and 99 Ϯ 12 mg/dl in the intensive insulin therapy group (P Ͻ 0.0001), with insulin doses of 12 (3-32) and 77 (57-98) IU/d, respectively (P ϭ 0.0002).
Mitochondrial fusion and fission
Protein levels of the mitochondrial fusion mediators mitofusin-2 and OPA1 and the mitochondrial fission mediator Drp1, but not Fis1, were increased above controls in liver of conventionally treated patients (Fig. 2A) . Patients who received intensive insulin therapy had comparable levels of mitofusin-2, Drp1, and Fis1 as controls, whereas OPA1 remained elevated. In postmortem rectus abdominis biopsies, critical illness had up-regulated the four proteins, irrespective of insulin treatment group ( Fig.  2A) . In contrast, vastus lateralis showed no up-regulation, whether taken in vivo ( Fig. 2A , without a difference between eventual survivors or nonsurvivors, data not shown) or postmortem (data not shown).
Mitochondrial biogenesis
Protein levels of nDNA-encoded (NDUFA9) and mtDNA-encoded (ND6) complex I subunits were upregulated in liver and rectus abdominis, but not in in vivo (Fig. 2B ) or postmortem (data not shown) vastus lateralis biopsies, of conventionally treated critically ill patients. Similar results, including also an increase in in vivo vastus lateralis muscle, were obtained for TFAM. Pol-␥ was upregulated only in liver. Protein levels of the mitochondrial biogenesis inhibitor RIP-140 were always comparable to controls. All tissues failed to up-regulate mtDNA levels. For all tissues, the patients in the normoglycemic, intensive insulin therapy group responded similarly as the hyperglycemic conventional group. Markers in in vivo vastus lateralis were comparable for eventual survivors and nonsurvivors (data not shown).
Discussion
Critical illness is associated with mitochondrial damage and impaired cellular energy metabolism, which have been implicated in organ dysfunction and adverse outcome. We demonstrated an up-regulation of several key mediators of mitochondrial fusion/fission and biogenesis in postmortem liver and rectus abdominis, but not in in vivo or postmortem vastus lateralis of the critically ill. Overall, maintenance of normoglycemia with insulin did not affect this response, except for a partial attenuation of mitochondrial fusion and fission markers in liver. We previously observed mitochondrial abnormalities, more pronounced in hyperglycemic than in normoglycemic livers (3) and, regardless of glycemic control, also impaired autophagy (6) . Together, our observations suggest that mitochondrial protection brought about by glycemic control is mediated by prevention of direct glucose toxicity, rather than via an effect on mitochondrial repair.
Mitochondria constantly undergo regulated fusion and fission, which determine mitochondrial morphology, organelle number, shape, size, content, distribution, and function (13, 14) . Fusion of nonfunctional, damaged mitochondria with healthy, fully functional mitochondria provides a mechanism to regain essential components and dilute molecular damage after subsequent fission (13) . However, giant mitochondria that accumulate within aged or diseased cells are unable to fuse and exchange contents with other mitochondria (7) . Recent findings put forward fission followed by selective fusion as quality control mechanism to segregate irreparable, dysfunctional mitochondria and target them for removal by autophagy   FIG. 2 . Mitochondrial fusion/fission and biogenesis in critically ill patients. Relative protein expression levels of several key mediators of mitochondrial fusion and fission (A) and mitochondrial biogenesis (B) were normalized to levels of cytokeratin-18 (liver) or to actin (skeletal muscle) and to levels of controls. These data as well as mtDNA levels (normalized to levels of controls, B) are shown as box plots, with medians, interquartile ranges and 10th and 90th percentiles. *, P Յ 0.05; (*), 0.05 Ͻ P Ͻ 0.1 vs. healthy reference; #, P Յ 0.05; (#), 0.05 Ͻ P Ͻ 0.1 between critically ill patients receiving conventional insulin therapy (CIT) or intensive insulin therapy (IIT). Representative blots are shown of, from left to right, three samples from controls and CIT and IIT patients each for liver and rectus abdominis and two controls followed by three to four CIT and IIT patients for vastus lateralis.
E62
Vanhorebeek 8) . Mitochondrial fission thus can generate two asymmetrical daughter organelles, one of which contains the defects. These fusion-incompetent mitochondria are then eliminated by autophagy. Importantly, increased fusion or reduced fission compromises autophagy (8) and may spare mitochondria from degradation (15) . Data on impact of critical injury on these processes are scarce and available only from experimental models. These suggest protection by mitofusin-2, whereas extensive fission may be detrimental by triggering apoptosis (16, 17) . Importantly, the two processes need to be appropriately balanced, because both unopposed fusion and unopposed fission are detrimental for cellular function. Proteins involved in fusion and fission were up-regulated in liver and rectus abdominis of our patients, but not in vastus lateralis. In liver, however, Fis1 was not increased. Although relative protein levels as such preclude conclusions on the balance between the processes, it could be speculated that fusion would prevail over fission, because Fis1 may be rate limiting (14) . This could further contribute to impaired targeting for mitophagy (8, 15) . The hepatic responses were partially attenuated with insulin therapy, either suggesting a reduced need for repair of mitochondrial damage in line with better-preserved structure and function (3) or, alternatively, a negative effect of insulin on mitochondrial repair. In animal models, severe sepsis induces oxidative mitochondrial damage, with decreased mtDNA copy number, mitochondrial transcription, and oxidative phosphorylation. Mitochondrial biogenesis is activated to restore the damage (9, 18, 19) . This response allows metabolic recovery and was put forward as a powerful prosurvival mechanism (9) . Indeed, skeletal muscle taken on d 1-2 in the ICU from critically ill patients showed a mitochondrial biogenesis response in survivors but not in nonsurvivors (20) . However, partial activation of this pathway failed to maintain mitochondrial function in skeletal muscle of patients with sepsis (21) . Likewise, activation of key regulators of mitochondrial biogenesis observed in our study did not affect mtDNA content and appeared insufficient to restore the functional mitochondrial damage (3). Vastus lateralis did not even show a clear response of the biogenesis program, irrespective of whether patients survived or not. Blood glucose control with insulin did not affect mitochondrial biogenesis.
Some limitations of our study need to be addressed. First, dynamic processes were investigated in steady state. Second, access to biopsies of critically ill patients is limited for obvious ethical reasons. Studying postmortem biopsies, although of acceptable quality from a technical viewpoint (3), may have introduced bias by studying the sickest patients or interference from postmortem phenomena.
However, vastus lateralis taken in vivo or postmortem showed a similar lack of response, in contrast to the increased marker protein levels in postmortem liver and rectus abdominis. This may suggest that muscle type (with rectus abdominis being more active along with respiration than the immobilized vastus lateralis) explains the different responses in both muscles, rather than survival status.
In conclusion, activation of the mitochondrial repair systems appeared insufficient in skeletal muscle and particularly in liver considering the persistence of severe morphological and functional mitochondrial abnormalities (3) . Preventing excessive hyperglycemia with insulin did not affect biogenesis and suppressed activation of fusion/ fission, which may reflect either a reduced need for diluting (less) damage during normoglycemia or, alternatively, a suppressive effect of insulin on repair. Together with the recently observed impaired activation of autophagy, these data are compatible with the hypothesis that the major driving force for the better preservation of mitochondrial ultrastructure and function with this therapy (3, 4) is a reduction in the damage directly inflicted by pronounced hyperglycemia on the mitochondria during critical illness, rather than an effect on the repair mechanisms. Because incomplete clearance of damaged mitochondria in vital organ systems, either by their repair or removal, as well as inappropriate replacement by new healthy mitochondria could contribute to organ dysfunction, the current observations open perspectives for therapies that effectively activate these mitochondrial repair mechanisms during critical illness.
